Related references
Note: Only part of the references are listed.Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Omar Abdel-Rahman et al.
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2014)
Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis
Tomohiro Funakoshi et al.
ACTA ONCOLOGICA (2013)
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
G. Procopio et al.
ANNALS OF ONCOLOGY (2013)
A randomized phase II study of lapatinib plus pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
Massimo Cristofanilli et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
Stephen R. D. Johnston et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
D. Cunningham et al.
BRITISH JOURNAL OF CANCER (2013)
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study
Jeffrey R. Infante et al.
CANCER (2013)
Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature
O. Abdel-Rahman et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Tyrosine Kinase Inhibitors and the Thyroid as both an Unintended and an Intended Target
Marion Vetter et al.
Endocrine Practice (2013)
Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma
Loredana Bianchi et al.
ENDOCRINE-RELATED CANCER (2013)
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
William J. Gradishar et al.
EUROPEAN JOURNAL OF CANCER (2013)
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2013)
Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
John P. Crown et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer North Central Cancer Treatment Group Study N0528
Grace K. Dy et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2013)
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma
Omar Abdel-Rahman et al.
MEDICAL ONCOLOGY (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
Sewanti Limaye et al.
ORAL ONCOLOGY (2013)
Tyrosine Kinase Inhibitor-Induced Thyroid Disorders: A Review and Hypothesis
Noriko Makita et al.
THYROID (2013)
Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside
Omar Abdel-Rahman
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2013)
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
A. Goncalves et al.
ANNALS OF ONCOLOGY (2012)
Does Sunitinib-Induced Hypothyroidism Play a Role in the Activity of Sunitinib in Metastatic Renal Cell Carcinoma?
Avishay Sella et al.
CHEMOTHERAPY (2012)
Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)
Kim A. Margolin et al.
CLINICAL CANCER RESEARCH (2012)
Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2012)
Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib
Julia Clemons et al.
CLINICAL GENITOURINARY CANCER (2012)
Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
Peter Mulders et al.
EUROPEAN JOURNAL OF CANCER (2012)
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
Katalin Boer et al.
INVESTIGATIONAL NEW DRUGS (2012)
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
A. B. El-Khoueiry et al.
INVESTIGATIONAL NEW DRUGS (2012)
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vandetanib Versus Placebo in Patients With Advanced Non-Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
Jin Soo Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
Paulo M. Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
Jonas Bergh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
Chiun Hsu et al.
JOURNAL OF HEPATOLOGY (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
Sophie Leboulleux et al.
LANCET ONCOLOGY (2012)
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
C. Gridelli et al.
ANNALS OF ONCOLOGY (2011)
Sunitinib for the treatment of metastatic renal cell carcinoma
Stephane Oudard et al.
CANCER TREATMENT REVIEWS (2011)
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
Masatoshi Kudo et al.
EUROPEAN JOURNAL OF CANCER (2011)
Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
Richard H. de Boer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Ronald B. Natale et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
Sylvie Negrier et al.
LANCET ONCOLOGY (2011)
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Hedy L. Kindler et al.
LANCET ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management
Rebecca L. Brown
TARGETED ONCOLOGY (2011)
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
L. M. Riesenbeck et al.
WORLD JOURNAL OF UROLOGY (2011)
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer
E. L. Mayer et al.
ANNALS OF ONCOLOGY (2010)
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
H. Wildiers et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H. Barrios et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial
Ghassan K. Abou-Alfa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
Glenwood D. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety and Efficacy of Combining Sunitinib with Bevacizumab plus Paclitaxel/Carboplatin in Non-small Cell Lung Cancer
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
Roy S. Herbst et al.
LANCET ONCOLOGY (2010)
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer
Jozsef Horti et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer
Nathalie Theou-Anton et al.
DRUG SAFETY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Vandetanib Versus Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
Ronald B. Natale et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Francesco Torino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study group
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
John V. Heymach et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A randomized, bouble-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with nonsmall cell lung cancer
Katsuyuki Kiura et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies
Doru T. Alexandrescu et al.
THYROID (2008)
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada clinical trials group study BR. 20
Andrew M. Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer
John V. Heymach et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20
A. M. Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
F Baffert et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
